You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Programming Metabolically Fit TILs for Immunotherapy

    SBC: Lipo-immuno Tech, LLC            Topic: NCI

    ABSTRACT Advances in molecular biology and genetic engineering have led to the design and use of modified T cells recognize tumors to achieve significant tumor control upon adoptive cell transfer (ACT) to patients. These T cells are either transduced with tumor antigen reactive T cell receptors (TCR), or chimeric antigen receptors (CARs). Recently, a surge in studies with neo-antigen reactive T ce ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Delivery of chemically modified PNA oligomers

    SBC: NUBAD, LLC            Topic: NIAID

    PROJECT SUMMARYRNA is a validated target for drug design, both as therapeutic and as a target. Targeting specific RNA, such as rRNA which are involved in proliferation and survival of bacteria is a promising approach. We are developing fast and low cost methods to screen sequence-specific small molecules for novel anti-ribosomal activities. We will construct sequence-specific chemically modified r ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Treatment of Proliferative Vitreoretinopathy using Aerosolized Methotrexate

    SBC: POWERSCOPE, INC            Topic: NEI

    Project Summary Proliferative vitreoretinopathy (PVR) is a major complication of retinal detachments and is responsible for most of the failures in retinal reattachment surgeries. About 10% of retinal detachment patients suffer from PVR. These patients often have poor visual outcome despite multiple surgeries. Our previous work on inhibition of PVR has focused on pharmacological intervention concu ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Microbial Synthesis of Therapeutic Bile Acids

    SBC: Metselex, Incorporated            Topic: NINDS

    ABSTRACT This Phase STTR Phase I proposal aims to engineer a synthetic metabolic pathway in a microbial host to produce UDCA and related compounds. The proposed work has high intellectual merit for the following reasons: (i) UDCA biosynthesis does not occur in any organism whose cultivation can be scaled to meet global demand, (ii) UDCA requires a multi-organism biosynthetic pathway (animal cholic ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: OD

    Abstract Duchenne Muscular Dystrophy (DMD) is a fatal muscle disease with a predicted incidence of 1 in 5000 males. DMD results from mutations in the gene encoding dystrophin, a 427 kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and laminin in the extracellular matrix. The 7β1 integrin is a transmembrane linkage system in skeleta ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Improving data capture in clinical research using a chatbot

    SBC: Dokbot, LLC            Topic: NLM

    PROJECT SUMMARY . Collecting complete and accurate outcome data directly from research participants is becoming increasingly important. Clinical researchers needs a cost-effective approach to capture high-quality patient-reported outcomes. Typically, data captured directly from participants is through self-administered questionnaires or through a human interviewer, each with their own advantages ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Analysis of new compounds to treat familial hypercholesterolemia

    SBC: GRUTHAN BIOSCIENCE LLC            Topic: NHLBI

    PROJECT SUMMARY The long-term goal of the current proposal is to generate a new class of small molecules to treat familial hypercholesterolemia. Familial hypercholesterolemia (FH) patients suffer from excessively high levels of Low Density Lipoprotein Cholesterol (LDL-C), which if left untreated results in death from severe cardiovascular disease. FH is caused primarily by mutations in the LDL rec ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles

    SBC: MarPam Pharma LLC            Topic: NIAID

    Abstract Building on our successful primate model studies, we aim to develop a one-time treatment for durable remission of human immunodeficiency virus (HIV) in the absence of antiretroviral medications. This treatment is an autologous HIV-specific chimeric antigen receptor (CAR, specifically CD4-MBL-CAR) T cell therapy that targets B cell follicles1,2. B cell follicles are an immune protected sit ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Simplified Transfemoral Carotid Angioplasty and Stenting Under FlowReversal Using a Novel Combination Access Sheath/Balloon System

    SBC: Marblehead Medical LLC            Topic: NHLBI

    PROJECT SUMMARYCarotid Artery Stenting (CAS) using embolic protection represents the current standard of care for patients with carotid artery stenosis considered at high risk for carotid endarterectomy. Distal filter devices are the most widely used protection devices, but these must be navigated through plaque prior to deployment, presenting a significant embolic risk. Strong evidence indicates ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Contamination resistant interconnection for reducing peritoneal dialysis- associated peritonitis

    SBC: Cerovations, LLC            Topic: 400

    Abstract Significance: Peritonitis remains a significant challenge in the management of end stage renal disease (ESRD) for patients on peritoneal dialysis (PD) and contributes significantly to morbidity and mortality. More than half of these infections result from bacteria originating on skin or mucous membranes, suggesting patient or caregiver contamination as the source of infections. Furthermor ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government